Brief: FDA Approves Ayvakit As First Treatment For Indolent Systemic Mastocytosis
22/05/2023 22:14
May 22 (Reuters) - Blueprint Medicines Corp BPMC.O :
* FDA APPROVES AYVAKIT® (AVAPRITINIB) AS THE FIRST AND ONLY
TREATMENT FOR INDOLENT SYSTEMIC MASTOCYTOSIS
Source text for Eikon: ID:nPn6c1V5Xa
Further company coverage: BPMC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Blueprint Medicines
See all newsBrief: Sanofi Announces Extension Of Blueprint Tender Offer
Brief: Blueprint Medicines Announces Data Reinforcing Safety Profile Of Long-Term Ayvakit
U.S. STOCKS ON THE MOVE-Texas Instruments, Broadcom, Circle
UBS raises Blueprint Medicines' PT on Sanofi's up to $9.5 billion takeover deal
U.S. RESEARCH ROUNDUP-Biomea Fusion, GE Aerospace, P&G